Acta Pharmacologica Sinica, Published online: 10 November 2026; doi:10.1038/s41401-026-01956-w Hesperetin ameliorates APAP-induced liver injury by activating a PKC–TFEB axis
Shu-jun Chen, et al. “Hesperetin ameliorates APAP-induced liver injury by activating a PKC–TFEB axis.” Acta Pharmacologica Sinica, 2026. doi:10.1038/s41401-026-01956-w.
@article{Chen2026,
title = {Hesperetin ameliorates APAP-induced liver injury by activating a PKC–TFEB axis},
author = {Chen, Shu-jun and Chen, Yi-xin and Zhao, Yu-jie and Zeng, Jing-min and Tan, Shi-yun and Wang, Hao and Wang, Li-rong and Chao, Xiao-juan and Wang, Shao-gui},
journal = {Acta Pharmacologica Sinica},
year = {2026},
doi = {10.1038/s41401-026-01956-w},
url = {https://www.nature.com/articles/s41401-026-01956-w}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...